ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On January 12, 2009, Celgene Corporation announced it will review 2008 achievements and provide outlook for 2009 milestones at the J.P. Morgan 27th Annual Healthcare Conference. For 2008, Celgene expects to exceed its annual guidance and advance multiple clinical, regulatory, commercial and financial initiatives in all areas of its global operations, underscored by European Commission approval for VIDAZAŽ and globalization of Celgene operations in more than 65 countries.

The information in this Report, including the exhibit attached hereto, is furnished solely pursuant to Item 2.02 of this Form 8-K and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Furthermore, the information in this Report, including the exhibit, shall not be deemed to be incorporated by reference into the filings of the Registrant under the Securities Act of 1933.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibit 99.1 - Press Release dated January 12, 2009

This exhibit is furnished pursuant to Item 2.02 and shall not be deemed to be "filed."